Publications by authors named "M Medhaffar"
Introduction: Imatinib is a first-line selective tyrosine kinase inhibitor used for the treatment of chronic myeloid leukemia. Although imatinib-induced hepatotoxicity may aggravate the patient's clinical condition and alter the treatment plan, the mechanism of imatinib-induced hepatotoxicity has rarely been investigated.
Case Report: We report a 51-year-old man, suffering from acute toxic hepatitis after 5 months of imatinib treatment for chronic myeloid leukemia.
Introduction: Palliative care is an approach that improves the quality of life of patients with advanced disease.
Objective: The aim of this study is to evaluate the process of palliative care in patients with hematologic malignancies.
Methods: In this prospective observational study, we included patients with hematologic malignancies who received palliative care over a 12 month period from June 1, 2019, to May 31, 2020 at the day care hospital of the hematology department in University Hospital of Sfax, Tunisia.
Background: The P-glycoprotein (P-gp) is one of the mechanisms of Imatinib (IM) resistance in chronic myeloid leukemia (CML). P-gp has been identified as an efflux pump involved in releasing of IM outside CML cells. To date, the P-gp involvement in the IM resistance development was not completely understood.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluated oxidative stress in chronic myeloid leukemia (CML) patients treated with imatinib (IM) compared to controls, and further analyzed differences based on IM resistance.
- The research involved 40 CML patients (26 of whom were IM-resistant) and 34 controls, measuring various oxidant and antioxidant markers using spectrophotometric methods.
- Results indicated higher levels of malondialdehyde (MDA) and advanced oxidation protein products (AOPP) in CML patients, with IM-resistant patients showing even greater oxidative stress and altered antioxidant activity, highlighting an adverse oxidative profile linked to treatment resistance.